Azacitidine Injection

DRUG13 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins All Children's Hospital, Andrew Dinardo, Ludwig-Maximilians - University of Munich, Nanexa AB

Conditions

AMLAML, ChildhoodAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia RefractoryB Acute Lymphoblastic LeukemiaC-KIT MutationChronic Myelomonocytic Leukemia (CMML)

Phase 1

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

CompletedNCT00005639

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2000-03-31End: 2005-07-31Updated: 2019-01-11

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Active, not recruitingNCT03843528

Johns Hopkins All Children's HospitalAcute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia +1

Start: 2019-05-01End: 2026-10-30Target: 15Updated: 2025-08-11

Azacytidine During Anti-tuberculosis Therapy

WithdrawnNCT03941496

Andrew DinardoTuberculosis, Pulmonary

Start: 2022-10-31End: 2023-05-31Updated: 2023-02-08

Pharmacokinetics, Tolerability and Safety of NEX-18a

CompletedNCT05048498

Nanexa ABAcute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndromes (MDS)

Start: 2021-04-27End: 2022-02-10Updated: 2023-10-17

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

RecruitingNCT05559008

Ruijin HospitalPeripheral T Cell Lymphoma

Start: 2022-09-30End: 2026-01-26Target: 116Updated: 2022-11-09

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

TerminatedNCT06150040

Centre Leon BerardAcute Myeloid Leukemia Refractory

Start: 2024-09-11End: 2025-02-18Updated: 2025-02-20

Phase 2

Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

RecruitingNCT04913922

Ludwig-Maximilians - University of MunichAcute Myeloid Leukemia

Start: 2021-05-05End: 2026-03-31Target: 30Updated: 2022-11-08

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

CompletedNCT05048615

Hospital Universitario Dr. Jose E. GonzalezAML

Start: 2021-07-26End: 2023-01-20Updated: 2023-01-25

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

The First Affiliated Hospital of Soochow UniversityB Acute Lymphoblastic Leukemia, High Risk Acute Lymphoblastic Leukemia, Ph-Negative ALL

Start: 2024-04-20End: 2025-09-10Target: 20Updated: 2024-04-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

RecruitingNCT06316960

Children's Hospital of Soochow UniversityAML, Childhood, C-KIT Mutation, Core Binding Factor Acute Myeloid Leukemia +2

Start: 2024-03-01End: 2027-03-31Target: 50Updated: 2024-08-22

Phase 3

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

RecruitingNCT06389292

Ascentage Pharma Group Inc.Acute Myeloid Leukemia

Start: 2024-06-11End: 2029-03-26Target: 486Updated: 2025-11-25

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

RecruitingNCT06641414

Ascentage Pharma Group Inc.Higher-risk Myelodysplastic Syndrome

Start: 2025-01-22End: 2029-12-31Target: 490Updated: 2025-11-20

Unknown Phase

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

Not yet recruitingNCT06279338

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMyelodysplastic Syndromes

Start: 2024-03-01End: 2026-01-31Target: 40Updated: 2024-02-28

Related Papers

Abstract CT225: AARON: An ongoing open-label phase I/II study of relatlimab (anti-LAG-3) with nivolumab (anti-PD-1) in combination with azacitidine ± venetoclax for the treatment of patients with relapsed/refractory and non-fit patients with newly diagnosed acute myeloid leukemia - Interim analysis

Cancer Research2025-04-254 citations

Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial

Blood2024-11-05

Outpatient Low-Dose Venetoclax Plus Azacitidine Vs. Intensive Chemotherapy for Newly Diagnosed Fit Patients with Acute Myeloid Leukemia in a Limited Resource Setting

Blood2023-11-023 citations

Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study

Leukemia Research2023-08-228 citations

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

Blood2022-11-156 citations

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Clinical Cancer Research2022-11-0930 citations